Publication date context: 2026 February 19 at 14 14 UTC accompanies a new invitational clinical study in Europe testing a novel air purifier for rare mucociliary disorders. The trial focuses on two respiratory diseases, Primary Ciliary Dyskinesia and Cystic Fibrosis. The device configuration under study uses a four stage filtration chain that includes a HEPA filter plus three other filters to improve particle filtration in the patient environment. A control configuration provides sham filtration for comparison. Sponsors listed are the University of Cyprus and the Horizon 2020 program of the European Commission. Enrollment is by invitation only.
What changed in testing for rare mucociliary disorders?
The document describes a trial design that compares two air purifier configurations. The intervention configuration applies HEPA filtration together with three additional filters to deliver enhanced particle filtration in the surrounding air. The control configuration is described as a sham filtration setup intended to provide a baseline for comparison without active filtration through the extra stages. The conditions under study are Primary Ciliary Dyskinesia and Cystic Fibrosis. Enrollment is by invitation, which suggests selective inclusion criteria not disclosed in the current summary. The sponsors identified are the University of Cyprus and the Horizon 2020 program of the European Commission. The emphasis is on environmental control rather than a drug or biologic product, aligning with regulatory expectations for device based studies.
How is the trial structured?
What devices are used?
The intervention device is described as an air purifier configured with four filter stages including HEPA to reduce airborne particulates. The comparator uses a sham configuration that provides no active filtration to enable a baseline comparison. The trial is described as a two configuration study rather than a drug trial. Enrollment is by invitation.
Who can participate?
Participation details are not specified in the source text beyond invitation based enrollment. Prospective participants would be drawn from clinical networks aligned with PCD and CF centers in Europe.
What is the role of sponsors and funding?
Funding is provided by Horizon 2020 and the University of Cyprus, indicating European research support for device oriented investigations in this field. The collaboration underscores a public private balance in the study.
What is the regulatory context for this trial?
The study presents as a medical device investigation and will be evaluated under European regulatory frameworks. The stated intended use is to filter ambient air to support respiratory mucociliary clearance; formal performance claims will require regulatory review under processes aligned with the MDR Annex XIV framework. The text notes manufacturer statements are not the basis of the summary; disclosures reflect sponsor communications.
What safety considerations apply to this device study?
As with any device trial focused on environmental filtration, the project will monitor device performance and user safety in real world settings. The description does not provide specific adverse event data, but the trial framework implies safety testing through standard device study protocols and sponsor oversight in line with EU guidance. Participants should rely on professional medical advice and the trial team for risk information and consent details.
Who funds and how can information be confirmed?
The study is sponsored by the University of Cyprus and supported through the Horizon 2020 program of the European Commission. For official information including trial status and protocol details, refer to the linked clinical trials registry entry.
- 1. What is the purpose of the trial? The trial evaluates a four filter air purifier and compares it with a sham configuration to assess environmental filtration in rare mucociliary disorders.
- 2. Who can participate? Enrollment is by invitation and details about eligibility are not published in the summary.
- 3. Where can I find more information? The primary public information source is the ClinicalTrials.gov entry linked below.
- 4. Who sponsors the study? The University of Cyprus and Horizon 2020 are listed as sponsors.
Conclusion
In summary, the invitational trial assesses a four stage air purifier approach against a sham control for PCD and CF, funded through Horizon 2020 and the University of Cyprus. Readers in regulatory and clinical quality roles should track the protocol and any updates toward regulatory submissions or guidance under EU device rules.
This information is for professional use only and does not constitute legal advice. It reflects the study summary as provided by sponsors and registries and should not be construed as a regulatory determination.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07417267?term=medical+device